Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales Reps Will Make Case For Ranexa In First-Line Angina

This article was originally published in The Pink Sheet Daily

Executive Summary

New label, which exceeded CV Therapeutics’ expectations, highlights reduction of hemoglobin A1c levels and arrhythmias.

You may also be interested in...



Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics

In a surprise move spurred by a desire to own a greater share of the promising angina drug Ranexa, Astellas announced Jan. 27 its hostile offer for partner CV Therapeutics in a cash deal worth roughly $1 billion

Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics

Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.

Astellas Looks To Increase U.S. Presence With Bid For CV Therapeutics

Japanese pharma tries to downplay appearance of hostile bid driven largely by interest in Ranexa.

Related Content

Topics

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel